

This listing of claims will replace all prior versions, and listings, of claims in the application.

I. Listing of Claims:

Claims 1-12. (Canceled)

~~13.~~ (Previously Amended) A peptide of the sequence:

X<sup>1</sup>m-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-X<sup>2</sup>n (SEQ

ID NO:2)

wherein X<sup>1</sup> and X<sup>2</sup> are each selected from the group consisting of L- or D- Arg,

His, Lys and Tyr, and m and n are each 0, 1, 2 or 3 with the proviso that at least m or n is 1;

a cyclic disulfide thereof or an organic or inorganic acid addition salt thereof.

Claims 14 and 15 (Canceled)

1  
3  
16. (Currently Amended) A peptide which is selected from the group consisting of

Leu Arg Ile Val Gln Pen Arg Ser Val Glu Gly Ser Pen Gly Phe (SEQ ID NO: 15),

CH<sub>3</sub>CO- Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID

NO: 8),

H - Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO:

12),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe - CONH<sub>2</sub> (SEQ

ID NO: 7),

Leu Arg Ile Val Gln Cys Lys Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 10),

Leu Arg Ile Val Gln Cys Lys Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 11),

\_\_\_\_\_(amide bond)

Tyr Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO:

19),

Lys Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO:

20),

Lys Lys Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID

NO: 33),

Ala Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 22),

Leu Lys Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 21),

Leu Arg Ala Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO:

23),

Leu Arg Lys Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 6),

Leu Arg Ile Ala Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 24),

Leu Arg Ile Val Ala Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 25),

Leu Arg Ile Val Gln Cys Arg Ala Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 27),

Leu Arg Ile Val Gln Cys Arg Ser Ala Glu Gly Ser Cys Gly Phe (SEQ ID NO: 28),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Ala Ser Cys Gly Phe (SEQ ID NO: 30),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ala Cys Gly Phe (SEQ ID NO: 31),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Ala Phe (SEQ ID NO: 17),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu D-Ala Ser Cys D-Ala Phe (SEQ ID NO:

14), and

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Ala (SEQ ID NO: 16), wherein all amino acids, except for glycine, are of the L-absolute configuration, unless indicated as D-absolute configuration, and the peptide has a cyclic disulfide bond between Cys(182) and Cys(189) or Pen(182) and Pen(189) as appropriate, or an organic or inorganic acid addition salt thereof.

Claims 17-35: (Canceled)

<sup>2</sup>36. (Currently Amended) A pharmaceutical composition for use in the treatment of obesity in an animal, which comprises an effective amount of a peptide according to claim 1, <sup>1</sup>18, together with one or more pharmaceutically acceptable carriers and/or diluents.

Claims 37-40: (Canceled)

<sup>5</sup>41. (Previously Added) A peptide which comprises an analogue of the carboxyl-terminal sequence of a growth hormone, said analog comprising the amino acid sequence:

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (SEQ ID NO:19)

wherein all amino acids, except for glycine, are of the L-absolute configuration, unless indicated as D-absolute configuration, and the peptide has a cyclic disulfide bond between Cys(182) and Cys(189) or an organic or inorganic acid addition salt thereof.

<sup>6</sup>42. (Currently Amended) A peptide according to claim 1, <sup>5</sup>41, of the sequence:

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (SEQ ID NO:19).

<sup>8</sup>~~43~~. (Previously Added) A pharmaceutical composition for use in the treatment of obesity in an animal, which comprises an effective amount of a peptide according to claim <sup>5</sup>~~41~~, together with one or more pharmaceutically acceptable carriers and diluents.

<sup>7</sup>~~44~~. (Previously Added) A pharmaceutical composition for use in the treatment of obesity in an animal, which comprises an effective amount of a peptide according to claim <sup>6</sup>~~42~~, together with one or more pharmaceutically acceptable carriers and diluents.

<sup>4</sup>~~45~~. (New) A pharmaceutical composition for use in the treatment of obesity in an animal, which comprises an effective amount of a peptide according to claim <sup>3</sup>~~16~~, together with one or more pharmaceutically acceptable carriers and/or diluents.

---